Active Clinical Studies

Protocol Title: Phase Ib/III, Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer

Principal Investigator: Mohammad Memon, MD

Indication: Locally Advanced (inoperable) or metastatic HR+/HER2- breast cancer 

Study Description: The purpose of this study is to learn more about treatment with an experimental drug called capivasertib, added to a standard of care treatment fulvestrant + CDK4/6i (palbociclib or ribociclib) for patients with advanced breast cancer and to better understand the studied disease and associated health problems.
 

Protocol Title: A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Principal Investigator: Ahmed Jouan, MD

Indication: Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Study Description: The purpose of this study is to see if an experimental drug, called milvexian in addition to standard of care, is safe and useful in reducing the risk of future ischemic stroke in subjects after ischemic stroke or transient ischemic attack compared to placebo (tablet with no active drug) in addition to standard of care. An experimental drug is one that is not approved by the United States Food and Drug Administration (FDA). 
 

Protocol Title: CLINICAL BIOSPECIMEN COLLECTION TO SUPPORT BIOMARKER RESEARCH

Principal Investigator: Robert Johnson, MD

Indication: Various Cancers

Study Description: To collect the biological specimens to use towards biomarker development and other technologies or treatment for oncology patients.